Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3…
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.
A novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies is defined, namely HPV+/p16 high (class III) in oropharyngeal squamous cell carcinoma.
Human papillomavirus in cervical and head-and-neck cancer
This Review summarizes the main events of the HPV life cycle, the functions of the viral proteins, and the implications of HPV infection on their hosts, with an emphasis on carcinogenic mechanisms and disease outcomes in head-and-neck cancer.
Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis
The AQUA system provides a continuous measurement of EGFR on paraffin-embedded tissue and was able to reveal the association between EGFR expression and outcome expected from the biological role of EG FR, and may be useful in predicting response to EGFR-targeted therapies.
Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management.
Various therapeutic aspects for primary gastric lymphomas are still controversial and several questions remain unanswered, among others, the role of rituximab, consolidation radiotherapy as well as H. pylori eradication in histological aggressive subtypes warrants better clarification.
Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer
In patients with oropharyngeal squamous cell carcinoma, overexpression of p16 as determined by immunohistochemistry is associated with significantly improved prognosis and lower local recurrence rates.
HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING,
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind,…
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
At the second interim analysis (IA2), P significantly improved OS in the phase 3 study of P or P + chemo (C) vs EXTREME (E) as 1L therapy for R/M HNSCC (NCT02358031).
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
It is demonstrated that detection of CTCs overexpressing PD-L1 is feasible and may provide important prognostic information in HNSCC, and suggest that adjuvant PD1 inhibitors deserve evaluation in H NSCC patients in whom PD- L1(+) C TCs are detected at the end of curative treatment.